by Silvia Prades | Oct 16, 2024 | News Articles
CureDRPLA was founded in November 2019 and in light of our forthcoming founding anniversary, we have prepared an impact report to summarize our work and milestones. In this report you will find a summary of our achievements to date and our goals for the next 5 years....
by Silvia Prades | Oct 11, 2024 | Events
In this session, Dr Silvia Prades will give an update on the projects funded by CureDRPLA. Followed by a Q&A session with Dr Yael Shiloh-Malawsky from the University of North Carolina and Dr Hector Garcia-Moreno from University College London, two neurologists...
by Silvia Prades | Oct 2, 2024 | News Articles
Last week, Dr Silvia Prades attended a conference to find out more about the latest work on rare diseases and how the medicines regulatory framework is expected to change in the coming years to facilitate research and approval of treatments for rare conditions like...
by Silvia Prades | Aug 9, 2024 | News Articles
CureDRPLA co-founders, Paul and Andrea Compton, have a son with DRPLA and their personal experiences with this devastating condition are the driving force behind CureDRPLA. Earlier this year, CureDRPLA announced that n-Lorem had an experimental treatment for DRPLA and...
by Silvia Prades | Jul 30, 2024 | News Articles
Nissan Chemical Corporation and Sanwa Kagaku Kenkyusho Co., Ltd., two Japanese companies, have announced they recently co-created an antisense oligonucleotide (ASO) for DRPLA. ASOs have emerged as a promising strategy for various neurodegenerative conditions,...
Recent Comments